Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The Prostate Cancer Prevention Trial and its implications for clinical practice: A European consensus

Teillac, Pierre and Abrahamsson, Per-Anders LU (2006) In European Urology. Supplement 5(9). p.640-646
Abstract
The findings from the Prostate Cancer Prevention Trial (PCPT) and how they relate to the management of prostate disease were reviewed by leading European urologists during a meeting held in December 2005. The consensus opinions that were reached were endorsed by the European Association of Urology and are documented here. The key points of the consensus are as follows: (1) The overall results from the PCPT are of importance to the urologic community. (2) The PCPT data provide additional support for the use of finasteride in the management of men with lower urinary tract symptoms (LUTSs)/benign prostatic hyperplasia (BPH). (3) It is recommended that prostate management guidelines be updated to include the results from both the Medical... (More)
The findings from the Prostate Cancer Prevention Trial (PCPT) and how they relate to the management of prostate disease were reviewed by leading European urologists during a meeting held in December 2005. The consensus opinions that were reached were endorsed by the European Association of Urology and are documented here. The key points of the consensus are as follows: (1) The overall results from the PCPT are of importance to the urologic community. (2) The PCPT data provide additional support for the use of finasteride in the management of men with lower urinary tract symptoms (LUTSs)/benign prostatic hyperplasia (BPH). (3) It is recommended that prostate management guidelines be updated to include the results from both the Medical Therapy of Prostatic Symptoms (MTOPS) Study and the PCPT. (4) The increased incidence of diagnosed high-grade cancer in the finasteride group compared with placebo is probably a consequence of improved detection. (5) For men who are concerned about prostate cancer, it may be appropriate to discuss chemoprevention with finasteride. (6) Urologists are encouraged to disseminate these recommendations among other health care professionals. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Prostate, prostate cancer, Therapy of Prostatic Symptoms (MTOPS) Study, Medical, finasteride, benign prostatic hyperplasia, chemoprevention, Cancer Prevention Trial (PCPT)
in
European Urology. Supplement
volume
5
issue
9
pages
640 - 646
publisher
Elsevier
external identifiers
  • wos:000238802300004
  • scopus:33744814101
ISSN
1569-9056
DOI
10.1016/j.eursup.2006.05.001
language
English
LU publication?
yes
id
873b8c7f-4db3-448c-b50c-fb39d2af8425 (old id 404174)
date added to LUP
2016-04-01 16:27:06
date last changed
2021-08-10 03:16:26
@article{873b8c7f-4db3-448c-b50c-fb39d2af8425,
  abstract     = {The findings from the Prostate Cancer Prevention Trial (PCPT) and how they relate to the management of prostate disease were reviewed by leading European urologists during a meeting held in December 2005. The consensus opinions that were reached were endorsed by the European Association of Urology and are documented here. The key points of the consensus are as follows: (1) The overall results from the PCPT are of importance to the urologic community. (2) The PCPT data provide additional support for the use of finasteride in the management of men with lower urinary tract symptoms (LUTSs)/benign prostatic hyperplasia (BPH). (3) It is recommended that prostate management guidelines be updated to include the results from both the Medical Therapy of Prostatic Symptoms (MTOPS) Study and the PCPT. (4) The increased incidence of diagnosed high-grade cancer in the finasteride group compared with placebo is probably a consequence of improved detection. (5) For men who are concerned about prostate cancer, it may be appropriate to discuss chemoprevention with finasteride. (6) Urologists are encouraged to disseminate these recommendations among other health care professionals. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.},
  author       = {Teillac, Pierre and Abrahamsson, Per-Anders},
  issn         = {1569-9056},
  language     = {eng},
  number       = {9},
  pages        = {640--646},
  publisher    = {Elsevier},
  series       = {European Urology. Supplement},
  title        = {The Prostate Cancer Prevention Trial and its implications for clinical practice: A European consensus},
  url          = {http://dx.doi.org/10.1016/j.eursup.2006.05.001},
  doi          = {10.1016/j.eursup.2006.05.001},
  volume       = {5},
  year         = {2006},
}